GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Amedisys Inc (NAS:AMED) » Definitions » Cash Flow from Investing

Amedisys (Amedisys) Cash Flow from Investing : $-14 Mil (TTM As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Amedisys Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Amedisys spent $3 Mil on purchasing property, plant, equipment. It gained $0 Mil from selling property, plant, and equipment. It spent $0 Mil on purchasing business. It gained $0 Mil from selling business. It spent $0 Mil on purchasing investments. It gained $0 Mil from selling investments. It paid $0Mil for net Intangibles purchase and sale. And it received $0 Mil from other investing activities. In all, Amedisys spent $3 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Amedisys Cash Flow from Investing Historical Data

The historical data trend for Amedisys's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amedisys Cash Flow from Investing Chart

Amedisys Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -352.95 -287.11 -281.61 -94.49 35.06

Amedisys Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.90 -7.75 -1.05 -2.04 -3.07

Amedisys Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Amedisys's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Amedisys's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amedisys  (NAS:AMED) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Amedisys's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-3 Mil. It means Amedisys spent $3 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Amedisys's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0 Mil. It means Amedisys gained $0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Amedisys's purchase of business for the three months ended in Mar. 2024 was $-0 Mil. It means Amedisys spent $0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Amedisys's sale of business for the three months ended in Mar. 2024 was $0 Mil. It means Amedisys gained $0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Amedisys's purchase of investment for the three months ended in Mar. 2024 was $0 Mil. It means Amedisys spent {stock_data.stock.currency_symbol}}0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Amedisys's sale of investment for the three months ended in Mar. 2024 was $0 Mil. It means Amedisys gained $0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Amedisys's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $-0 Mil. It means Amedisys paid $0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Amedisys's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0 Mil. It means Amedisys paid $0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Amedisys's cash from other investing activities for the three months ended in Mar. 2024 was $0 Mil. It means Amedisys received $0 Mil from other investing activities.


Amedisys Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Amedisys's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Amedisys (Amedisys) Business Description

Traded in Other Exchanges
Address
3854 American Way, Suite A, Baton Rouge, LA, USA, 70816
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
Executives
Allyson Guidroz officer: Chief Accounting Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard M Ashworth director, officer: President and CEO 200 WILMOT ROAD, DEERFIELD IL 60015
Michael Paul North officer: Chief Information Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Adam Y Holton officer: Chief People Officer C/O CHS INC., 5500 CENEX DRIVE, INVER GROVE HEIGHTS MN 55077
Denise M. Bohnert officer: Chief Compliance Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Nick Muscato officer: Chief Strategy Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard A Lechleiter director PO BOX 32890, LOUISVILLE KY 40232-2890
Bruce D Perkins director 500 WEST MAIN STREET, LOUISVILLE KY 40202
Christopher Gerard officer: Chief Operating Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Teresa L. Kline director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeffrey A Rideout director 2142 DEER OAK WAY, DANVILLE CA 94506
Julie D Klapstein director 1239 FRUIT COVE ROAD NORTH, JACKSONVILLE FL 32259
Molly Joel Coye director AETNA INC, 151 FARMINGTON AVENUE, HARTFORD CT 06156
David L Kemmerly officer: See Remarks 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816